Distribution, elimination, and renal handling of 99mtechnetium- demogastrin 1

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 2, 2012, Pages 169-174

  Trejtnar, Frantisek ^a   Laznickova, Alice ^a   Laznicek, Milan ^a   Novy, Zbynek ^a   Maina, Theodosia ^b   Nock, Berthold A ^b   Behe, Martin ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c ETH Zurich   (Switzerland)

Author keywords

CCK gastrin receptors; liver excretion; pharmacokinetics; receptor specific peptides; renal excretion

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; DEMOGASTRIN 1; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; GLOMERULUS FILTRATION; INTESTINE; ISOTOPE LABELING; KIDNEY PERFUSION; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RADIOACTIVITY; RAT; STOMACH; URINARY EXCRETION;

ANIMALS; GASTRINS; ISOTOPE LABELING; KIDNEY; LIVER; MALE; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ B; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 84858390079     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1008     Document Type: Article

References (35)

1. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008;49:1735.
2. Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 2009;71:199.
3. Bodei L, Ferone D, Grana CM, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2009; 32:360.
4. Ansquer C, Kraeber-Bodéré F, Chatal JF. Current status and perspectives in peptide receptor radiation therapy. Curr Pharm Des 2009;15:2453.
5. de Herder WW, Lamberts SW. Somatostatin and somato-statin analogues: Diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53.
6. De Jong M, Breeman WA, Kwekkeboom DJ, et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009;42:873.
7. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996;67:644.
8. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-2/gastrin receptors in human tumors. Cancer Res 1997; 57:1377.
9. Schaer JC, Reubi JC. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: Comparison with CCK-A and CCK-2 receptor contents. J Clin Endocrinol Metab 1999;84:233.
10. Upp JR Jr, Singh P, Townsend CM Jr, Thompson JC. Clinical significance of gastrin receptors in human colon cancers. Cancer Res 1989;49:488.
11. Weinberg DS, Ruggeri B, Barber MT, et al. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J Clin Invest 1997; 100:597.
12. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA-and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481.
13. Ertay T, Unak P, Bekis R, et al. New radiolabeled CCK-8 analogues Tc-99m-GH-CCK-8 and Tc-99m-CCK-8: Preparation and biodistribution studies in rats and rabbits. Nucl Med Biol 2001;28:667.
14. Roosenburg S, Laverman P, van Delft FL, et al. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2011;41:1049.
15. Behr TM, Jenner N, Radetzky S, et al. Targeting of chole-cystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424.
16. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029.
17. Mather SJ, McKenzie AJ, Sosabowski JK, et al. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48:615.
18. 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J Nucl Med 2009;50:591.
19. Von Guggenberg E, Sallegger W, Helbok A, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: Preclinical evaluation. J Med Chem 2009; 52:4786.
20. Nock BA, Maina T, Behe M, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727.
21. Béhé M, Becker W, Gotthardt M, et al. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: Preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140.
22. Fröberg AC, de Jong M, Nock BA, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scin-tigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1265.
23. Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97.
24. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radi-olabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010;51:1049.
25. Trejtnar F, Laznicek M, Laznickova A, Mather SJ. Pharma-cokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med 2000;41:177.
26. Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1956;1:470.
27. Láznicková A, Láznicek M, Kvetina J, Drobnik J. Pharma-cokinetics and plasma protein binding of two platinum cy-tostatics CHIP and CBDCA in rats. Cancer Chemother Pharmacol. 1986;17,133.
28. Laznickova A, Laznicek M, Trejtnar F, et al. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1- octreotide in rats. Eur J Drug Me-tab Pharmacokinet 2002;27:37.
29. Zarzuelo A, Sánchez-Navarro A, Lopez FG, Lanao JM. A review of the isolated kidney as an experimental model for pharmacokinetic studies. Methods Find Exp Clin Pharmacol 2000;22:757.
30. Laznicek M, Laznickova A, Trejtnar F, et al. Lanreotide labeled with 99mTc: Preparation, preclinical testing and comparison with (111)In-DTPA- octreotide. Anticancer Res 2002;22:2125.
31. Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals. J Nucl Med 1997;38:829.
32. Behe M, Kluge G, Becker W, et al. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012.
33. Trejtnar F, Laznicek M, Laznickova A, et al. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer Res. 2007;27:907.
34. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552.
35. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847.